| Literature DB >> 27057435 |
Andreas Mock1, Christel Herold-Mende1.
Abstract
Immune monitoring assays for patient stratification and treatment efficacy in clinical trials are in demand. We have recently described a cost-effective non-invasive assay to determine the immune status of glioblastoma patients. Profiling antitumor serum antibodies by customized printed peptide arrays identified response against a tenascin-C (TNC) peptide as a robust prognostic biomarker.Entities:
Keywords: Antibodies; TNC; glioblastoma; long-term survival; non-invasive; biomarker; serum
Year: 2015 PMID: 27057435 PMCID: PMC4801449 DOI: 10.1080/2162402X.2015.1069941
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110